Skip to main content
Premium Trial:

Request an Annual Quote

David Ferrick

Premium

David Ferrick has been named vice president of biology and clinical applications at Guava Technologies, the company said on July 6.

Ferrick was previously CEO and director of Sarges Discovery, a Davis, Calif.-based oncogenome research and cancer drug discovery company that Ferrick co-founded in 1999, Guava said. Prior to this, he served as director of molecular and cellular biology at Rigel Pharmaceuticals.

Ferrick also has held numerous academic positions, including associate professor in the department of pathology, microbiology, and immunology at the University of California, Davis. He has also worked at the Ontario Cancer Research Center and the Walter Reed Army Institute. He holds a PhD in immunology from Georgetown University.

 

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.